利用可调压脑室腹腔分流管作为脑室内给药装置量化脑室内药物递送
该单中心回顾性分析纳入2003至2020年15例伴可调压脑室腹腔分流管的CNS肿瘤患者,用In-111-DTPA闪烁显像评估22次脑脊液流动研究,全部研究显示脑室-鞘内药物活性,73%研究腹膜相对摄取极低(<12%),27%为中等(12-37%),无研究腹膜摄取超过37%。
要点
- 15例患者共22次闪烁显像研究均显示In-111-DTPA成功递送至脑室-鞘内空间。
- 73%(16/22)研究腹膜相对摄取极低(<12%),27%(6/22)为中等(12-37%),无研究超过37%。
- 共识别6种可调压分流管型号,疗效因型号而异,但样本量小无法得出型号优劣结论。
核心结论
- 所有患者均成功将In-111-DTPA递送至脑室-鞘内空间,73%的患者腹膜相对药物摄取极低(<12%)。
- 疗效因分流管型号而异,但样本量小无法得出型号优劣的结论。
- 脑脊液流动闪烁显像研究可评估In-111-DTPA的药物分布,为脑室内治疗的脑脊液流动提供信息。
研究设计与样本
- 单中心回顾性分析,纳入2003至2020年伴可调压脑室腹腔分流管的CNS肿瘤患者15例,共进行22次脑脊液流动研究。
- 使用In-111-DTPA闪烁显像在2-4小时和24小时量化脑室-鞘内和腹膜药物活性,并记录分流管型号。
- 评估可调压脑室腹腔分流管作为脑室内治疗接入装置的成功率。
主要发现
- 15例患者诊断包括髓母细胞瘤、转移性神经母细胞瘤、松果体母细胞瘤和脉络丛癌,共识别6种不同可调压脑室腹腔分流管型号。
- 100%的研究(22/22)显示脑室-鞘内药物活性。
- 27%(6/22)的研究成像未见腹膜摄取;73%(16/22)的研究腹膜相对摄取极低(<12%)。
- 27%(6/22)的研究显示中等腹膜相对摄取(12-37%);无研究显示腹膜摄取超过37%。
局限性
- 原文为单中心回顾性分析。
- 样本量小(15例患者,22次研究),无法就分流管型号优劣得出结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Programmable ventriculoperitoneal shunts (pVP shunts) are increasingly utilized for intraventricular chemotherapy, radioimmunotherapy, and/or cellular therapy. Shunt adjustments allow optimization of drug concentrations in the thecal space with minimization in the peritoneum. This report assesses the success of the pVP shunt as an access device for intraventricular therapies. Quantifying intrathecal drug delivery using scintigraphy by pVP shunt model has not been previously reported. METHODS: We performed a single-institution, retrospective analysis on patients with CNS tumors and pVP shunts from 2003 to 2020, noting shunt model. pVP flow was evaluated for consideration of compartmental radioimmunotherapy (cRIT) using In-111-DTPA scintigraphy. Scintigraphy studies at 2-4 h and at 24 h quantified ventricular-thecal and peritoneal drug activity. RESULTS: Twenty-two CSF flow studies were administered to 15 patients (N = 15) with diagnoses including medulloblastoma, metastatic neuroblastoma, pineoblastoma, and choroid plexus carcinoma. Six different types of pVP models were noted. 100% of the studies demonstrated ventriculo-thecal drug activity. 27% (6 of 22) of the studies had no peritoneal uptake visible by imaging. 73% (16 of 22) of the studies had minimal relative peritoneal uptake (< 12%). 27% (6 of 22) of the studies demonstrated moderate relative peritoneal uptake (12-37%). No studies demonstrated peritoneal uptake above 37%. CONCLUSIONS: All patients had successful drug delivery of In-111-DTPA to the ventriculo-thecal space. 73% of the patients had minimal relative (< 12%) peritoneal drug uptake. Though efficacy varies by shunt model, low numbers preclude conclusions regarding model superiority. CSF flow scintigraphy studies assesses drug distribution of In-111-DTPA, informing CSF flow for delivery of intraventricular therapies.
引用
- McThenia SS, Pandit-Taskar N, Grkovski M, et al. Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device. J Neurooncol. 2022. PMID: 35403968. doi:10.1007/s11060-022-03989-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。